首页> 外文OA文献 >The Effect of Three-Monthly Albendazole Treatment on Malarial Parasitemia and Allergy: A Household-Based Cluster-Randomized, Double-Blind, Placebo-Controlled Trial
【2h】

The Effect of Three-Monthly Albendazole Treatment on Malarial Parasitemia and Allergy: A Household-Based Cluster-Randomized, Double-Blind, Placebo-Controlled Trial

机译:三个月阿苯达唑治疗对疟疾寄生虫病和过敏的影响:家庭为基础的簇随机,双盲,安慰剂对照试验。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background; Helminth infections are proposed to have immunomodulatory activities affecting health outcomes either detrimentally or beneficially. We evaluated the effects of albendazole treatment, every three months for 21 months, on STH, malarial parasitemia and allergy.udMethods and Findings: A household-based cluster-randomized, double-blind, placebo-controlled trial was conducted in an area in Indonesia endemic for STH. Using computer-aided block randomization, 481 households (2022 subjects) and 473 households (1982 subjects) were assigned to receive placebo and albendazole, respectively, every three months. The treatment code was concealed from trial investigators and participants. Malarial parasitemia and malaria-like symptoms were assessed in participants older than four years of age while skin prick test (SPT) to allergens as well as reported symptoms of allergy in children aged 5-15 years. The general impact of treatment on STH prevalence and body mass index (BMI) was evaluated. Primary outcomes were prevalence of malarial parasitemia and SPT to any allergen. Analysis was by intention to treat. At 9 and 21 months post-treatment 80.8% and 80.1% of the study subjects were retained, respectively. The intensive treatment regiment resulted in a reduction in the prevalence of STH by 48% in albendazole and 9% in placebo group. Albendazole treatment led to a transient increase in malarial parasitemia at 6 months post treatment (OR 4.16(1.35- 12.80)) and no statistically significant increase in SPT reactivity (OR 1.18(0.74-1.86) at 9 months or 1.37 (0.93-2.01) 21 months). No effect of anthelmintic treatment was found on BMI, reported malaria-like- and allergy symptoms. No adverse effects were reported.udConclusions: Vre study indicates that intensive community treatment of 3 monthly albendazole administration for 21 months over two years leads to a reduction in STH. This degree of reduction appears safe without any increased risk of malaria or allergies
机译:背景;蠕虫感染被认为具有免疫调节活性,有害或有益于影响健康结果。我们评估了阿苯达唑治疗每3个月(共21个月)对STH,疟疾寄生虫病和过敏的影响。 ud方法和结果:在美国加利福尼亚州的一个地区进行了一项基于家庭的集群随机,双盲,安慰剂对照试验。印度尼西亚是STH的地方病。使用计算机辅助区组随机分配,每三个月分别分配481户家庭(2022名受试者)和473户家庭(1982年受试者)接受安慰剂和阿苯达唑。对于试验研究者和参与者,隐藏了治疗法规。对年龄大于4岁的参与者进行了疟疾寄生虫血症和类似疟疾的症状评估,同时对过敏原进行了皮肤点刺试验(SPT)并报告了5-15岁儿童的过敏症状。评估了治疗对STH患病率和体重指数(BMI)的总体影响。主要结局是疟原虫血症和SPT对任何过敏原的患病率。分析是按意向进行的。在治疗后9个月和21个月,分别保留了80.8%和80.1%的研究对象。强化治疗方案使阿苯达唑的STH患病率降低了48%,而安慰剂组的STH患病率降低了9%。阿苯达唑治疗在治疗后6个月导致疟疾寄生虫病短暂增加(OR 4.16(1.35- 12.80)),而SPT反应性无统计学显着性提高(9个月时OR 1.18(0.74-1.86)或1.37(1.33-0.91) 21个月)。未发现对BMI有驱虫治疗作用,未报告有类似疟疾和过敏的症状。结论:Vr e研究表明,两年内给予3个月的阿苯达唑3个月一次的强化社区治疗可导致STH降低。这种降低程度似乎是安全的,不会增加疟疾或过敏的风险

著录项

  • 作者

    Firdaus Firdaus;

  • 作者单位
  • 年度 2013
  • 总页数
  • 原文格式 PDF
  • 正文语种 en
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号